[Comment] Expanding the post-EGFR TKI landscape with antibody–drug conjugates
Source 柳叶刀 Lancetjust now
Summary
Third-generation EGFR tyrosine kinase inhibitors (TKIs), increasingly combined with chemotherapy or amivantamab, are the preferred front-line treatment for EGF…
We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.
Open original- Desk
- Health
- Region
- United Kingdom
- Language
- English
- Item ID
- health-21d17421
Comments 0 comments
No comments yet. Be the first.